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ABSTRACT 
Purpose: A retrospective study was done to investigate the long-term outcome of patients 
treated with lower energy transurethral microwave thermotherapy. 
Materials and Methods: A total of 305 patients with lower urinary tract symptoms and benign 
prostatic hypertrophy underwent transurethral microwave thermotherapy according to a similar 
protocol at 2 centers. 
Results: After 3 years of followup 133 patients who had undergone transurethral microwave 
thermotherapy alone were available for study. During this observation period significant symp- 
tomatic improvement from baseline and an improved maximum flow rate of 2.6 ml. per second 
were noted. Of the patients 125 underwent invasive or medical treatment. 
Conclusions: After 3 years of followup lower energy transurethral microwave thermotherapy 
showed significant and durable improvements in baseline parameters in  52% of the  patients. 
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During the last decade many different alternatives to sur- 
gical resection of the prostate in patients with lower urinary 
tract symptoms and benign prostatic hyperplasia (BPH) have 
been introduced, including use of different oral medications, 
such as 5a-reductase inhibitors and a1-adrenergic antago- 
nists, as well as several minimally invasive approaches.l.2 
Although surgical resection effectively relieves bladder outlet 
obstruction with a consequent decrease in symptoms, the 
popularity of these alternative therapeutic options in the 
treatment of BPH is based on the potential decrease in mor- 
bidity and costs. The use of heat applied by different gener- 
ators (for example ultrasound, radiofrequency, laser and mi- 
crowave devices), appears to be the most promising 
alternative.3-6 Transurethral microwave thermotherapy of- 
fers great potential as an outpatient anesthesia-free 
1-session procedure. Presently, of the many different ther- 
motherapy devices the Prostatron* unit has received the 
most attention and has been investigated extensively with 
more than 25,000 treatments performed worldwide. Several 
studies of this device report substantial and significant sub- 
jective improvement. An overall improvement rate of approx- 
imately 70% in the Madsen-Iversen symptom score7 com- 
pared to baseline usually is noted. Improvement in urinary 
performance also is encouraging, with improvement in max- 
imum flow rate of approximately 2 to 3 ml. per second (ap- 
proximately 35%) from baseline and a similar decrease in 
post-void residual of approximately 35%.6 The mechanism of 
action may be related to thermal damage of prostate tissue 
and not to the effect of urethral manipulation as shown 
by several randomized studies of transurethral microwave 
thermotherapy versus sham therapy.8. 9 More importantly, 
Dahlstrand et a1 showed that the symptomatic improvement 
that occurred after transurethral microwave thermotherapy 
was statistically identical to that noted after transurethral 
resection of the prostate.10 However, the effect of transure- 
thral microwave thermotherapy on uroflowmetry parameters 
was less pronounced compared to that of transurethral re- 
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section. Subjective and objective parameters remained stable 
for 3 years of observation.6 
We have gained a large experience with the Prostatron 
device. Since the end of 1990 treatments with the lower 
energy protocol (Prostasoft version 2.0) have been performed. 
We conducted a retrospective study of patients treated with 
this protocol at  2 different centers and report the long-term 
results. 
MATERIAL AND METHODS 
From December 1990 to December 1992, 305 men with 
lower urinary tract symptoms and BPH were treated with 
the Prostatron device. Pretreatment assessment included pa- 
tient history with Madsen-Iversen symptom scores: physical 
examination with digital rectal examination, urinalysis, 
urine culture, transrectal ultrasound of the prostate with 
calculation of prostate volume using the formula of Terris 
and Stamey,ll and uroflowmetry with measurement of post- 
void residual by abdominal ultrasound of the bladder using 
the ellipsoid technique. 
The majority of patients were included in a range of pro- 
spective trials conducted according to more or less similar 
protocols. Criteria to enter the study were patient age older 
than 45 years, lower urinary tract symptoms longer than 3 
months in duration, a Madsen-Iversen symptom score of 8 or 
more, urinary maximum flow of 15 ml. per second or less and 
post-void residual of 350 ml. or less. Exclusion criteria were 
urinary retention, prostate carcinoma, acute or chronic pros- 
tatitis, urethral stricture, intravesical pathological condition 
(stones or neoplasm), neurogenic bladder dysfunction, uri- 
nary tract infection, isolated enlargement of the middle lobe, 
use of drugs influencing bladder or prostate function, disor- 
ders of blood flow or coagulation and diabetes mellitus. 
Transurethral microwave thermotherapy has been de- 
scribed previously.12 After treatment patients were asked to 
remain in the department until satisfactory voiding had been 
established. In case of retention a urethral catheter was 
placed, usually for 1 week. All patients were treated a t  least 
3 years ago. Data on symptom scores and uroflowmetry re- 
sults were analyzed retrospectively at baseline, and 12, 24 
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and 36 months after treatment. Maximum flow was corrected 
for artifacts by 2 independent observers using the 2-second 
method.13 Voided volume was correlated with post-void re- 
sidual to provide a voiding fraction using the formula: per- 
cent voiding fraction = voided volume/(voided volume + post- 
void residual).'* 
In case of further surgical or medical intervention the date 
and type of treatment were noted. When a patient did not 
return for further followup and there was no outcome record 
in the file a detailed questionnaire including the Madsen- 
Iverson symptom score was mailed to the patient. If the 
Madsen-Iverson symptom score was missing at the 3-year 
visit to the outpatient clinic a score was obtained via tele- 
phone interview. A patient was considered lost to followup if 
there were no data after the last visit to the outpatient clinic 
despite several attempts to contact him via mail or telephone. 
If a patient was not satisfied with the result of transurethral 
microwave thermotherapy and, therefore, he took medica- 
tions for the lower urinary tract symptoms (5a-reductase, an 
Q blocker or anticholinergics) or underwent surgery the uro- 
flowmetry or symptom score data were not considered when 
evaluating followup results. Finally, posttreatment morbid- 
ity was noted if the patient experienced urinary incontinence, 
urethral stricture or other treatment related complaints. 
RESULTS 
Of the 305 patients 73 were treated in London and 232 in 
Nijmegen. The former patients on average had smaller pros- 
tates, voided with larger volumes, had a larger post-void 
residual and, consequently, had a smaller voiding fraction. 
All other parameters used in the study were equally distrib- 
uted and statistically similar (table 1). For the total group 
mean age a t  baseline plus or minus standard deviation was 
65.3 2 7.3 years (range 45 to 87) and average prostate vol- 
ume was 48.6 ? 20.7 ~ m . ~  (range 15 to 133). After 3 years of 
followup 133 patients, who had no additional medical or 
surgical treatment, were available for study (table 2). Of 140 
letters mailed to patients 99 were returned and 41 men were 
considered lost to followup. If no data were available at  1 
and/or 2 years and the patient returned for further followup 
after 3 years or when he completed the mailed questionnaire 
he was considered to have had a missed visit at 1 andor 2 
years of followup. 
Table 3 shows the paired data for improvement in the main 
indexes from baseline. After 1 year there was a 56% decrease 
in symptom score that gradually decreased further to 53 and 
34% at 2 and 3 years of followup, respectively. Nevertheless, 
symptoms remained statistically improved over baseline. Im- 
provement in maximum flow remained stable a t  24, 20 and 
27% of cases after 1, 2 and 3 years of followup, respectively. 
Improvement in post-void residual and voiding fraction also 
remained constant for the 3 years of observation, although 
improvement in voided percentage over baseline was no 
longer statistically significant at 3 years. This finding may be 
due to the small number of patients whose uroflowmetry data 
were available at this visit. 
TABLE 1. Baseline characteristics for the 2 centers 
Mean 2 SD 
Nijmegen London Value 
(232 pts.) (73 pts.) 
Pt. age (yrs.) 64.9 t 7.2 66.8 2 7.5 0.051 
hos ta t e  vol. ( ~ m . ~ i  49.9 2 19.7 43.6 2 23.4 0.031* 
Madsen-Iverson symptom score 12.7 % 3.5 13.5 2 3.4 0.070 
Uroflowmetry: 
Max. flow rate (mlhec.) 9.0 2 2.8 9.4 2 2.7 0.375 
Voided vol. (rn1.i 223 t 113 258 2 121 0.045* 
Post-void residual (m1.i 65 2 68 139 -t 98 CO.OOl* 
?4 Voiding fraction 79 t 18 68 2 19 <0.001* 
* Significant difference, Student's t test, a = 0.05. 
TABLE 2. Number of patients, additional treatments and losses to 
followup 
No. Pts. 
1 2 3 T o ~ l N o . P t s .  
Yr. Yrs. Yrs. 
bansurethral microwave thermotherapy only 233 112 133 133 
Invasive pmedure after prior use of medica- 2 9 5 16 
64 22 23 19 Invasive pmedure 
Death 1 2 3  6 
17 19 5 41 Lost to followup 
Missed visit 12 69 - - 
Medication 18 11 16 45 
tion 
At baseline 305 patients underwent transurethral microwave thermother- 
apy alone. 
Stratification of the data for patients treated with trans- 
urethral microwave thermotherapy alone by the percentage 
change in outcome a t  1, 2 and 3 years of followup as a 
definition of success as suggested by Food and Drug Admin- 
istration guidelines is shown in table 4. The proportion of 
patients with 50% or more symptomatic improvement re- 
mained stable during the first 2 years and decreased to 39% 
at 3 years of followup. The proportion of patients with 50% or 
more improvement in maximum flow remained durable at  
26, 23 and 27% a t  1, 2 and 3 years of followup, respectively. 
Except for the greater symptomatic improvement a t  1 year 
for the London patients, there appeared to be no statistically 
significant difference between the London and Nijmegen 
groups in amount of improvement in any main index (table 
5). At 3 years of followup 133 of 258 patients (52%) with 
available data had undergone transurethral microwave ther- 
motherapy alone. Overall, 80 of 219 men (31%) underwent an 
invasive procedure, including a second transurethral micro- 
wave thermotherapy in 8, transurethral resection of the pros- 
tate in 45, incision of the prostate in 3, laser prostatectomy in 
17, suprapubic prostatectomy in 5 and radical prostatectomy 
after diagnosis of prostate cancer in 1. 
Of the 258 patients 60 (23%) were not satisfied with the 
result of transurethral microwave thermotherapy and they 
began medical therapy (42 with (Y blockers, 5 with 5a- 
reductase and 12 with anticholinergic drugs). One patient 
began flutamide therapy when prostate cancer was diag- 
nosed. Of these men 16 were not content with medical ther- 
apy and they finally underwent surgical intervention. The 
figure illustrates the Kaplan-Meier plot of early termination 
of the study due to starting medication and undergoing an 
invasive procedure. Patients waited an average of 1.4 ? 0.8 
years (range 0.5 to 2.9) before initiating medical therapy and 
1.5 5 0.8 years (range 0.25 to 2.9) before undergoing surgery 
due to dissatisfaction with the result after transurethral 
microwave thermotherapy. 
No statistically significant difference in any baseline pa- 
rameter was found at 3 years after transurethral microwave 
thermotherapy between patients who had a 50% or greater 
response in symptom score or maximum flow and those who 
underwent subsequent medical or surgical treatment. After 
treatment 82 of 305 patients (27%) required a transurethral 
catheter due to urinary retention, which was removed 1 week 
after treatment in the majority of patients. Three of 258 
patients (1.2%) had recurrent urinary tract infections requir- 
ing antibiotics, 8 (3.1%) had prolonged macroscopic hematu- 
ria, 1 (0.4%) had a urethral stricture and 4 (1.6%) had urge 
incontinence. Finally, 4 patients were diagnosed with pros- 
tate cancer by prostate biopsies (2) and histology of resected 
tissue after transurethral resection of the prostate (2). 
DISCUSSION 
The aim of any treatment for lower urinary tract symptoms 
and BPH is to achieve symptomatic relief with a correspond- 
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TABLE 3. Followup paired data for baseline parameters in patients undergoing transurethral microwave thermotherapy without 
additional treatment 
1961 
1 Yr. 2 Yrs. 3 Yrs. 
Baseline 12 Mos. p Value Baseline 24 Mos. p Value Baseline 36 Mos. p Value 
Baseline ~ 
Madsen-Iverson 
symptom score: 
No. pts. 305 208 66 113 
Mean 2 SD 12.9 t 3.5 12.8 -C 3.3 5.6 f 4.6 <0.001* 13.0% 3.0 6.1 f 5.3 <0.001* 12.2 2 8.1 8.1 f 5.8 <0.001* 
Uroflowmetry: 
30 - 
25 - 
$ 2 0 -  
B 
5 
.- 
a 
= - 1 5 -  
0 1 0 -  
5 -  
No. pts. 305 228 110 63 
Mean m a .  flow 9.1 2 2.8 9.2 f 2.7 11.4 f 4.2 <0.001* 9.3 f 2.8 11.2 f 4.1 <0.001* 9.4 f 2.9 11.9 2 4.7 <0.001* 
..... 
...... .... ... 
. . .  lnvasive ........ I.. 
-Medication ... d ..... ,../. 
..... 
.... 
I’ 
rate -t SD (m1.1 
sec.) 
% SD (ml.) 
residual ? SD 
(ml.) 
fraction % SD 
(%I 
Mean voided vol. 228 2 112 235 f 117 224 % 111 0.220 254 f 136 239 f 114 0.153 230 f 110 216 2 97 0.392 
Mean post-void 82 f 83 7 5 %  75 4 8 2  71 <0.001* 74 f 74 5 0 2  68 0.002* 62 f 56 4 8 2  77 0.008* 
Mean voiding 77 2 19 79 2 17 85 IT 17 <0.001* 80 % 16 8 4 %  16 0.015* 80 % 14 84 % 19 0.117 
* Significant via the Wilcoxon matched pairs signed ranks test, a = 0.05. 
TABLE 4. Response rates of main indexes after 1, 2 and 3 years in 
patients undergoing transurethral microwave thermotherapy alone 
shown as percent of patients with available data 
% Improvement From Baseline 
Par am e te r 
Less More More 
Than25 25-50 Than50 Than75 
Madsen-Iverson symptom score at yr.: 
1 19 21 60 34 
2 23 15 62 26 
3 48 13 39 27 
1 54 20 26 15 
2 57 20 23 14 
3 51 22 27 18 
Max. flow rate (ml./sec.) at yr.: 
TABLE 5. Difference in improvement in baseline parameters 
Mean 2 SD 
London Nijmegen 
p Value 
Madsen-Iversen symptom score at yr: 
1 9.2 2 4.6 6.5 % 4.9 0.001* 
2 8.5 f 5.8 5.8 f 5.7 0.065 
3 5.9 f 6.2 3.8 2 5.9 0.210 
1 2.7 f 3.8 2.0 -C 3.7 0.249 
2 1.6 2 3.8 1.9 f 4.3 0.701 
Max. flow rate (ml./sec.) at yr.: 
3 1.7 f 7.2 2.6 f 4.0 0.560 
* Significant via Student’s t test for independent samples, a = 0.05. 
ing decrease in bladder outlet obstruction. Symptomatic im- 
provement is determined by a decrease in symptom scores. 
Traditionally, symptomatic efficacy of transurethral micro- 
wave thermotherapy is evaluated with the Madsen-Iverson 
symptom score, which was the only commonly used symptom 
score at  the time of the initial trials in 1991. Decreased 
bladder outlet obstruction is usually evaluated by increased 
urinary flow rate since urodynamic pressure-flow studies are 
not usually applied. A treatment outcome can be expressed 
as mean changes or a percentage improvement in the param- 
eters. Short-term results with these methods of evaluation 
and morbidity of transurethral microwave thermotherapy 
have been extensively reported.6 However, data on the dura- 
bility of this treatment and re-treatment rate are limited to 
only a few reports.g.15.16 
Our 56% improvement rate at 1 year of followup is lower 
than the approximately 70% improvement rate reported in 
the literature. The same finding accounts for the objective 
maximum flow improvement of 2.2 ml. per second (24%), 
0 
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Follow-up in days 
Kaplan-Meier plot presenting early termination of study. Each 
individual line represents cumulative percentage of dropouts of pa- 
tients. 
which also is slightly less compared to the 3 to 4 ml. per 
second (approximately 35%) improvement in maximum flow 
reported in the literature. Finally, the 36% decrease in post- 
void residual seems to be more comparable, although data 
were limited and reports varied from 22 to 69% improve- 
ment.6 On the other hand, the percentage improvement from 
baseline in main outcome indexes using the Food and Drug 
Administration stratification guidelines was similar to that 
of prior studies. Our study showed 50% or greater improve- 
ment in symptom scores and maximum flow rate in 60 and 
26% of patients, respectively. Data from the literature re- 
vealed 50% or greater improvement in symptoms and maxi- 
mum flow rate in 62 and 36% of patients, respectively.8 
Furthermore, our study showed that the achieved improve- 
ment in symptoms and urinary performance remained dura- 
ble and more or less stable for a 3-year observation period, 
which is in accordance with others who reported 2 and 3-year 
followup data in a randomized study of transurethral micro- 
wave thermotherapy versus transurethral resection of the 
prostate.6.9 Nevertheless, there appeared to be a trend to- 
ward deterioration in symptoms with duration of followup, 
and that at  3 years the mean Madsen-Iversen symptom score 
was 8.1, which was just above the entry level of our study, 
particularly when one considers that patients without addi- 
tional treatment at  3 years of followup represent the best 
responders. 
Where should transurethral microwave thermotherapy be 
placed among all available treatment options for patients 
with lower urinary tract symptoms and BPH? The objective 
improvement after lower energy transurethral microwave 
thermotherapy is not comparable to what is achieved after 
surgical resection of the prostate as shown by Dahlstrand et  
al.9 The magnitude of improvement in urinary performance 
seems to be more in the ranges achieved with medical ther- 
apy. In an open extension North American study Stoner 
reported significant improvement in maximum flow from 
baseline values of 2.4 ml. per second in 156 patients 36 
months after beginning finasteride treatment.' Lepor re- 
ported similar changes in 103 patients treated with terazosin 
after 3 years of followup.2 Improvement in maximum flow 
ranged from 2.3 to 4.0 ml. per second greater than the base- 
line value a t  3 to 42 months of followup, with 30% or more 
improvement in flow in 40 to 59% of patients. However, 
patients still using medication at  3 years of followup should 
also be considered the best responders, which inherently 
skew the data. Tables 3 and 4 show similar improvements at  
3 years after transurethral microwave thermotherapy with a 
2.5 ml. per second improvement in flow and 25% or greater 
improvement in 49% of patients. Also, symptomatic improve- 
ments with the alternative treatment options seem to be 
more or less comparable. Since the studies reporting on long- 
term followup use different symptom scores to evaluate treat- 
ment outcome, the only way to compare these studies is by 
using the relative or percentage improvement. Lepor docu- 
mented a 30% or greater improvement in symptom score in 
62 to 77% of patients at  3 to 42 months of observation.2 
Stoner reported a mean decrease in symptom score of 3.6 
points after 36 months in the extended study of finasteride.l 
However, although improvement was significant compared 
to baseline values and to the placebo control group, it only 
accounted for approximately 18% improvement overall. Our 
study of transurethral microwave thermotherapy showed 
that symptomatic improvement after 3 years was 4.1 points, 
which accounted for 34% improvement over baseline. Fur- 
thermore, a 25% or greater improvement was achieved in 
52% of patients (table 3). 
Another point that must be addressed in evaluation of 
transurethral microwave thermotherapy is the repeat treat- 
ment rate. Every treatment option for lower urinary tract 
symptoms and BPH has a failure rate. In the case of initial 
surgical treatment, further surgery is performed because of 
complications (urethral stricture or bladder neck sclerosis) or 
recurrent disease. Table 2 shows that repeat invasive treat- 
ment after initial transurethral microwave thermotherapy 
was necessary in 24 of 287 (8%), 32 of 224 (14%) and 24 of 173 
(14%) of patients with available data at 1, 2 and 3 years of 
followup, respectively, which accounts for a total of 80 of 258 
(31%) requiring re-treatment in 3 years. The United States 
Prostatron transurethral microwave thermotherapy group 
recently presented the long-term results of a Food and Drug 
Administration study.17 In contradistinction to our study, 
they reported a significantly lower re-treatment rate of 11% 
after transurethral resection of the prostate. However, 29% 
of the men reported to have changed to some form of medical 
treatment. These differences are likely to  be explained by 
difference in department policy. In our study many patients 
were treated with laser prostatectomy due to several proto- 
cols that were conducted with this modality at  that time, 
whereas in the United States it appeared that medication 
was the first choice of treatment when patients did not ex- 
perience improvement after transurethral microwave ther- 
motherapy. Nevertheless, the United States and our studies 
noted a comparable and significant improvement in 52 and 
51% of patients at 3 and 4 years of followup, respectively. 
Available data in the literature on re-treatment rates after 
surgical resection of the prostate have some flaws, since the 
reported 1.8 to 15.5% re-treatment rate mainly depended on 
the observation period.18 The largest documented retrospec- 
tive study is that of Roos et al, who reported on 50,000 
patients undergoing transurethral resection of the prostate 
between 1963 and 1985.19 The re-treatment rate for a second 
prostatectomy was 2.3 to 4.3, 8.9 to 9.7 and 12.0 to 15.5% 
after 1,5 and 8 years, respectively. In this respect the United 
States long-term results appear to be comparable and, since 
none of the transurethral prostatectomy studies reported 
re-treatment with medication, the overall re-treatment rates 
&er transurethral microwave thermotherapy and transure- 
thral resection of the prostate might actually be similar. 
Unfortunately, neither the finasteride nor terazosin studies 
reported on the fate of patients whose treatment was consid- 
ered to have failed. 
Our re-treatment rate in patients treated with transure- 
thral microwave thermotherapy was greater than that after 
transurethral resection of the prostate. However, a price 
must be paid in terms of morbidity. In this respect transure- 
thral microwave thermotherapy seems to be favorable. We 
only reported minor complications after transurethral micro- 
wave thermotherapy except for the 27% retention rate, which 
is much greater than the reported 6.5% rate noted after 
surgical intervention.20 Since transurethral microwave ther- 
motherapy is an invasive procedure a urethral stricture rate 
of 0.4% (1 of 258 cases) can be considered slight compared to 
the 2 to 20% incidence after surgery.21 No patient reported 
stress incontinence although 4 (1.6%) experienced urge in- 
continence after transurethral microwave thermotherapy, 
possibly due to detrusor instability. Finally, the incidence of 
prostate cancer in only 4 of 258 patients (1.6%) appears to be 
low compared to available data on prostatectomy studies, 
which may be explained by the fact that patients were 
screened before entry into the study and that only 50 of 258 
(19%) actually had available histological data from resected 
tissue. 
Like several other clinical reports of transurethral micro- 
wave thermotherapy, our study showed a great interindi- 
vidual difference in treatment outcome regarding objective 
and subjective parameters, which has led many investigators 
to search for selection criteria that could predict clinical 
outcome. A multicenter study of responders versus nonre- 
sponders to transurethral microwave thermotherapy showed 
that none of the baseline clinical parameters could predict 
treatment outcome.22 Our study supports this conclusion, 
since no difference in the main treatment indexes was found 
between patients who could be considered to have a good 
response at  3 years of followup and those in whom treatment 
actually failed. To date the only predictive factor for treat- 
ment outcome can be obtained from urodynamic studies with 
pressure-flow analysis as demonstrated by Tubaro et a1 in a 
European multicenter study.22 Patients with constrictive 
urodynamic obstruction showed favorable improvement in 
symptoms and voiding parameters over those with predomi- 
nantly compressive obstruction.22 
Furthermore, thermometry studies have shown that not 
all prostates reach the maximum temperature intended, be- 
cause the thermoregulation of tissue in every patient differs 
signifi~antly.~3 In addition, the correlation between the 
achieved intraprostatic temperature and treatment outcome 
suggests that the greater the intraprostatic temperature, the 
better the clinical results.24 This finding has led to modifica- 
tion of the treatment software by increasing rectal threshold 
temperature and energy levels, resulting in fewer interrup- 
tions during treatment and a mean 40% increase in total 
energy delivered to the prostate.25 Initial clinical experience 
in phase I1 studies with high energy transurethral micro- 
wave thermotherapy using Prostasoft version 2.5 has shown 
increased objective improvement with comparable symptom- 
atic irnpro~ernent.~~.26 The relief of urodynamic bladder out- 
let obstruction and a cavity on transrectal ultrasound of the 
prostate 3 months after high energy transurethral micro- 
wave thermotherapy might also indicate improved efficacy 
and durability in the long term. 
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In conclusion, lower energy transurethral microwave ther- 
motherapy results in significant symptomatic improvement 
in 52% of patients, while objective improvement is approxi- 
mately 3 ml. per second at 3 years of followup. The short- 
term and long-term morbidity is acceptably low. 
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